Upon long-term treatment with LDE225, the RNA levels of the known SHH pathway genes Ptch1, Smo, Gli1, and Gli2 were equivalent to those in control-treated tumors in SD-CSC medulloblastomas (Fig. 2A), indicating continued activation of the SHH pathway consistent with acquired mutations in this pathway. The gene discussed is SMO; the disease is medulloblastoma.